Rationale and design of the IRON ‐CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy

ConclusionsThe IRON ‐CRT trial will determine the effect of ferric carboxymaltose on cardiac reverse remodelling and rate‐dependent cardiac contractility in HFrEF patients.

Source: ESC Heart Failure - September 27, 2019 Category: Cardiology Authors: Pieter Martens, Matthias Dupont, Jeroen Dauw, Frauke Somers, Lieven Herbots, Philippe Timmermans, Jan Verwerft, Wilfried Mullens Tags: Study Design Source Type: research